Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Government-funded Hong Kong Startup Looks To Run Traditional Chinese Medicine Treatment For IBS Through Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Developing a treatment for irritable bowel syndrome has proven to be an elusive goal and there is no product available in Asia to fully treat the disease, but a government-funded Hong Kong startup hopes a traditional Chinese medicine can stand the rigors of pharmaceutical approvals and fill an unmet medical need
Advertisement

Related Content

Sucampo/Takeda’s Amitiza First To Fill Zelnorm Void In IBS Market
Sucampo/Takeda’s Amitiza First To Fill Zelnorm Void In IBS Market
Advertisement
UsernamePublicRestriction

Register

SC071549

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel